BARCELONA—There was no improvement in biochemical progression free survival among patients who had their high-risk localized prostate cancers treated...
BARCELONA – For patients with locally advanced cervical cancer, combining intracavitary and interstitial (IC/IS) brachytherapy techniques...
BARCELONA – The 3rd European Society for Radiotherapy & Oncology Forum — ESTRO — was held this year in Barcelona featuring all aspects of...
BARCELONA—Men with intermediate- or high-risk prostate cancer who were treated with low dose rate prostate brachytherapy (LDR-PB) were twice as often...
BARCELONA – Brachytherapy with or without external beam radiation improved survival in patients with early-stage, inoperable endometrial cancer...
GENEVA— The IGNITE study from Chinese researchers has demonstrated how plasma—and not just tissue samples—could be used to distinguish patients with...
GENEVA—An alternative way of testing for mutated EGFR in patients with advanced non-small cell lung cancer was validated in research presented at the...
GENEVA— Almost one in four patients with advanced lung cancer in Europe, Asia and the US are not receiving EGFR test results before being started on...
Growing Evidence that Anti BRAF Melanoma Drugs Benefit Some Patients with Non-Small Cell Lung Cancer
GENEVA—Findings from the retrospective EURAF study suggest that many patients with BRAF-mutant lung cancers could benefit from treatment with BRAF...
GENEVA—Two thirds of patients with advanced non-small cell lung cancer that had failed first line anti-EGFR therapy responded to a new drug: AZD9291...
GENEVA—Reviews of CD8-positive T-cell infiltration as an independent prognostic biomarker in resected non-small cell lung cancer, and the potential...
GENEVA—First or second-line chemotherapy with cisplatin-pemetrexed or gemcitabine does not preclude the use of checkpoint inhibitor therapy for...